Cerebral Regional Tissue Oxygen Saturation to Guide Oxygen Delivery in Preterm Neonates During Immediate Transition (COSGOD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03166722

Recruitment Status : Recruiting

First Posted : May 25, 2017

Last Update Posted : January 11, 2022

See Contacts and Locations

Sponsor:

Collaborator:

Royal Alexandra Hospital

Information provided by (Responsible Party):

Medical University of Graz

Study Description

Brief Summary:

The aim of the COSGOD Phase III trial is to examine, if it is possible to increase survival without cerebral injury in preterm neonates <32 weeks of gestation by monitoring the cerebral tissue oxygen saturation in addition to routine monitoring of arterial oxygen saturation and heart rate and specified clinical treatment guidelines during immediate transition period after birth (the first 15 minutes).

Condition or disease	Intervention/treatment	Phase
Preterm Infant Brain Injuries Birth Hypoxia	Other: Control group Device: Study group	Not Applicable

Show detailed description

Detailed Description:

Background

The transition to life after birth is a complex physiological process where the neonate has to establish sufficient ventilation and changes from intra-uterine circulation to extra-uterine circulation take place. During these processes the neonate has to provide the brain with adequate perfusion and oxygen delivery to maintain normal cerebral tissue oxygenation and activity. If hypoxia and bradycardia both common events during immediate transition in preterm neonates occur, cerebral hypoxia-ischaemia may cause perinatal brain injury that is the major causes of mortality and long term neurodevelopmental impairment.

Objectives

The primary objective of the COSGOD Phase III trial is to examine, if it is possible to increase survival without cerebral injury in preterm neonates <32 weeks of gestation by monitoring the cerebral tissue oxygen saturation in addition to routine monitoring of arterial oxygen saturation (SpO2) and heart rate (HR) and specified clinical treatment guidelines during immediate transition period after birth (the first 15 minutes).

Hypothesis

The investigators hypothesise that using cerebral tissue oxygen saturation in addition to SpO2 and HR monitoring and specified treatment guidelines during immediate transition and resuscitation would increase survival without cerebral injury in preterm neonates.

Trial design

An investigator-initiated randomised, multi-centre, multinational, phase III clinical trial involving preterm infants from European countries and North America.

Inclusion and exclusion criteria

The inclusion criteria are: neonates born more than 8 weeks preterm (gestational age up to 31 weeks and 6 days); decision to conduct full life support; parental informed consent; and cerebral NIRS oximeter placed within three minutes after birth.

Sample size

According to actual data of two European centres (Graz and Rotterdam) and one Canadian centre (Edmonton) the percentage of neonates not affected by mortality and cerebral injury is 65%. Assuming an increase of not affected neonates from 65% to 75% and a dropout rate of 10% a total of 724 neonates are required to detect this difference with a two group χ² test (alpha: 0.05, power: 80%).

Intervention

The premature infants will be randomised into experimental or control group. Both groups will have a near infrared spectroscopy (NIRS) device (left frontal), pulse-oximeter (right wrist) and electrocardiogram placed within three minutes after birth. In the study group, the cerebral tissue saturation, SpO2 and HR readings are visible, and the infant will be treated accordingly using a defined treatment guideline. In the control group, only SpO2 and HR will be visible, and the infant will be treated according routine treatment.

Duration of intervention Monitoring will be started within 3 minutes after birth and the intervention will last during immediate transition period and resuscitation up to 15 minutes after birth.

Follow up

Thereafter, each neonate will be followed up for primary outcome to term date or discharge.

Outcome measures

The primary outcome is mortality and/or cerebral injury defined as any intraventricular bleeding and/or cystic periventricular leucomalacia.

The secondary outcomes are neonatal morbidities.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	726 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Intervention Model Description:	investigator-initiated randomised multi-centre multinational clinical trial
Masking:	Single (Outcomes Assessor)
Primary Purpose:	Diagnostic
Official Title:	Cerebral Regional Tissue Oxygen Saturation to Guide Oxygen Delivery in Preterm Neonates During Immediate Transition After Birth: An Investigator-initiated Randomised Multi-centre Multinational Clinical Trial
Actual Study Start Date :	September 20, 2017
Estimated Primary Completion Date :	February 28, 2022
Estimated Study Completion Date :	February 28, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Oxygen Therapy

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Study group: Invos 5100 Supplemental oxygen support and respiratory/circulatory support is guided by cerebral regional tissue oxygenation (crSO2) measured with near-infrared spectroscopy ("INVOS 5100" ), in addition to the SpO2/HR (oxygen saturation/heart rate) monitoring according to routine.	Device: Study group Cerebral NIRS measurement with INVOS 5100 during immediate transition in addition to SpO2 and HR monitoring
Active Comparator: Control group: Routine care Supplemental oxygen support and respiratory/circulatory support is guided by SpO2/HR monitoring according to routine - The resuscitation team is blinded to the crSO2 monitoring.	Other: Control group SpO2 and HR monitoring and routine treatment during immediate transition

Outcome Measures

Primary Outcome Measures :

Mortality and/or occurrence of cerebral injury [ Time Frame: up to 19 weeks after birth ]
Number of patients, who die or have intraventricular hemorrhage or have periventricular leucomalacia

Secondary Outcome Measures :

Frequency of neonatal morbidities [ Time Frame: up to 19 weeks after birth ]
Number of patients, who have infection and/or sepsis and/or necrotizing enterocolitis bronchoplumonary dysplasia, retinopathia prematurorumand/or bronchoplumonary dysplasia and /or retinopathia prematurorum
Sex [ Time Frame: up to 19 weeks after birth ]
Number of male and female patients, who die or have intraventricular hemorrhage or have periventricular leucomalacia
Gestational age [ Time Frame: up to 19 weeks after birth ]
Number of patients with less than 28 weeks of gestation and more than or equal 28 weeks of gestation, who die or have intraventricular hemorrhage or have periventricular leucomalacia

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	up to 15 Minutes (Child)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Preterm neonates less than completed 32 weeks,
Decision to conduct full life support,
Written informed consent.

Exclusion Criteria:

No decision to conduct full life support,
No written informed consent,
Congenital malformation.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03166722

Contacts

Layout table for location contacts

Contact: Gerhard Pichler, MD	+43 316 385 80520	gerhard.pichler@medunigraz.at

Locations

Layout table for location information

Austria
Department of Pediatrics, Medical University of Graz	Recruiting
Graz, Styria, Austria, 8036
Contact: Gerhard Pichler, MD 0043 316 385 80520 gerhard.pichler@medunigraz.at
Principal Investigator: Gerhard Pichler, MD
Medical University Innsbruck	Recruiting
Innsbruck, Austria
Contact: Ursula Kiechl-Kohlendorfer, Prof
Medical University Vienna	Recruiting
Vienna, Austria
Contact: Angelika Berger, Prof
Canada, Alberta
Royal Alexandra Hospital	Recruiting
Edmonton, Alberta, Canada, T5H 3V9
Contact: Georg M Schmölzer, MD, PhD georg.schmoelzer@me.com
Germany
Universitätsklinikum Freiburg	Recruiting
Freiburg, Germany
Contact: Hans Fuchs, Prof
Centre for Pediatric Clinical Studies	Recruiting
Tübingen, Germany
Contact: Laila Springer, MD
Ireland
University College Cork	Recruiting
Cork, Ireland
Contact: Eugene Dempsey, Prof
Italy
Ospedale dei Bambini "V.Buzzi" Milano	Recruiting
Milano, Italy
Contact: Gianluca Lista, Prof
Institute for Maternal and Child Health, IRCCS Burlo Garofolo	Recruiting
Trieste, Italy
Contact: Francesco Maria Risso, MD
Poland
Poznan University of Medical Sciences	Recruiting
Poznań, Poland
Contact: Jan Mazela, Prof
Uniwersytetu Medycznego im. Karola Marcinkowskiego	Recruiting
Poznań, Poland
Contact: Tomasz Szczapa, Prof
Slovenia
University Medical Centre Ljubljana	Recruiting
Ljubljana, Slovenia
Contact: Lilijana Kornhauser-Cerar, MD

Sponsors and Collaborators

Medical University of Graz

Royal Alexandra Hospital

Investigators

Layout table for investigator information

Principal Investigator:	Gerhard Pichler, MD	Medical University of Graz, Austria
Principal Investigator:	Georg M Schmölzer, MD, PhD	Royal Alexandra Hospital, Edmonton, Canada

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Pichler G, Baumgartner S, Biermayr M, Dempsey E, Fuchs H, Goos TG, Lista G, Lorenz L, Karpinski L, Mitra S, Kornhauser-Cerar L, Avian A, Urlesberger B, Schmölzer GM. Cerebral regional tissue Oxygen Saturation to Guide Oxygen Delivery in preterm neonates during immediate transition after birth (COSGOD III): an investigator-initiated, randomized, multi-center, multi-national, clinical trial on additional cerebral tissue oxygen saturation monitoring combined with defined treatment guidelines versus standard monitoring and treatment as usual in premature infants during immediate transition: study protocol for a randomized controlled trial. Trials. 2019 Mar 20;20(1):178. doi: 10.1186/s13063-019-3258-y.

Layout table for additonal information

Responsible Party:	Medical University of Graz
ClinicalTrials.gov Identifier:	NCT03166722
Other Study ID Numbers:	COSGOD Phase III
First Posted:	May 25, 2017 Key Record Dates
Last Update Posted:	January 11, 2022
Last Verified:	January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	Yes
Plan Description:	The demographic data and data of primary and secondary outcome will be stored at and available form the Institut for Medical Informatics, Statistics und Documentation, Medical University of Graz, Austria
Supporting Materials:	Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF)
Time Frame:	After publication of primary and secondary outcome
Access Criteria:	On demand

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

Additional relevant MeSH terms:

Layout table for MeSH terms

Brain Injuries Premature Birth Hypoxia Obstetric Labor, Premature Obstetric Labor Complications Pregnancy Complications Brain Diseases	Central Nervous System Diseases Nervous System Diseases Craniocerebral Trauma Trauma, Nervous System Wounds and Injuries Signs and Symptoms, Respiratory

To Top